ATE278957T1 - Verfahren zur unterstützung der diagnose der alzheimerschen krankheit durch messung der amyloid-beta-peptide(x groesser als oder gleich 41) und tau - Google Patents

Verfahren zur unterstützung der diagnose der alzheimerschen krankheit durch messung der amyloid-beta-peptide(x groesser als oder gleich 41) und tau

Info

Publication number
ATE278957T1
ATE278957T1 AT95939892T AT95939892T ATE278957T1 AT E278957 T1 ATE278957 T1 AT E278957T1 AT 95939892 T AT95939892 T AT 95939892T AT 95939892 T AT95939892 T AT 95939892T AT E278957 T1 ATE278957 T1 AT E278957T1
Authority
AT
Austria
Prior art keywords
alzheimer
diagnosis
disease
tau
aiding
Prior art date
Application number
AT95939892T
Other languages
English (en)
Inventor
Peter A Seubert
Carmen Vigo-Pelfrey
Dale B Schenk
Robin Barbour
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26991508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE278957(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/339,141 external-priority patent/US6114133A/en
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of ATE278957T1 publication Critical patent/ATE278957T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT95939892T 1994-11-14 1995-11-13 Verfahren zur unterstützung der diagnose der alzheimerschen krankheit durch messung der amyloid-beta-peptide(x groesser als oder gleich 41) und tau ATE278957T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/339,141 US6114133A (en) 1994-11-14 1994-11-14 Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US41900895A 1995-04-07 1995-04-07
PCT/US1995/014659 WO1996015452A1 (en) 1994-11-14 1995-11-13 METHODS FOR AIDING IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE BY MEASURING AMYLOID-β PEPTIDE (X- ≥41) AND TAU

Publications (1)

Publication Number Publication Date
ATE278957T1 true ATE278957T1 (de) 2004-10-15

Family

ID=26991508

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95939892T ATE278957T1 (de) 1994-11-14 1995-11-13 Verfahren zur unterstützung der diagnose der alzheimerschen krankheit durch messung der amyloid-beta-peptide(x groesser als oder gleich 41) und tau

Country Status (11)

Country Link
US (4) US7427392B1 (de)
EP (2) EP1491889A3 (de)
JP (2) JP3634375B2 (de)
AT (1) ATE278957T1 (de)
AU (1) AU705907B2 (de)
CA (1) CA2205359C (de)
DE (1) DE69533623T2 (de)
DK (1) DK0792458T3 (de)
ES (1) ES2230551T3 (de)
PT (1) PT792458E (de)
WO (1) WO1996015452A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
CN1325491A (zh) * 1998-09-08 2001-12-05 基因创新有限公司 作为早期CNS损伤标记物的τ
EP2082749A3 (de) * 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Vorbeugung und Behandlung für Morbus Alzheimer
EP1975179A1 (de) * 2001-12-26 2008-10-01 Araclon Biotech, S.L. Polyklonale Antikörper, Herstellungsverfahren und Verwendung
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
ES2246105B1 (es) * 2003-05-08 2007-03-01 Araclon Biotech, S.L. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
JP2008519988A (ja) * 2004-11-12 2008-06-12 ファイザー・インク アミロイド−ベータペプチドを測定する方法
WO2007044094A1 (en) * 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
BRPI0709050B1 (pt) * 2006-03-23 2018-12-26 Bioarctic Neuroscience Ab anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
AU2008204335B2 (en) 2007-01-11 2013-06-13 Michael Bacher Diagnosis and treatment of Alzheimer's and other neurodementing diseases
EP1944314A1 (de) * 2007-01-11 2008-07-16 Philipps-Universität Marburg Diagnose von Morbus Alzheimer und anderen Demenzerkrankungen
US20080249058A1 (en) * 2007-04-05 2008-10-09 Erik Roberson Agents that reduce neuronal overexcitation
EP2009445A1 (de) * 2007-06-29 2008-12-31 Institut Pasteur Verwendung von Einzeldomänen-Camelid-Antikörpern zur Entdeckung einer oligomeren Form eines Amyloid-Betapeptids und deren Anwendungen
EP2020602A1 (de) * 2007-08-02 2009-02-04 Araclon Biotech Hochempfindliche Immuntests und Kits zur Bestimmung biologisch interessanter Peptide und Proteine
EP2401617A4 (de) * 2009-02-24 2012-09-26 Winton G Gibbons Nachweis von komplexen aus tau und amyloid
EP3978517A1 (de) * 2009-03-18 2022-04-06 AC Immune SA Verfahren zur therapeutischen verwendung
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
EP2258398A1 (de) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin/Amyloidpeptid-Konjugate und deren Verwendungen
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
ES2496341T3 (es) 2011-10-04 2014-09-18 Affiris Ag Procedimiento para detectar anticuerpos Aß-específicos en una muestra biológica
DE102011057021A1 (de) * 2011-12-23 2013-06-27 Forschungszentrum Jülich GmbH Verfahren zur selektiven Quantifizierung von A-Beta-Aggregaten
JP5850374B2 (ja) 2012-01-27 2016-02-03 パナソニックヘルスケア株式会社 アルツハイマー病の診断補助方法、及び診断システム
EP2834270B1 (de) 2012-04-05 2019-10-30 AC Immune S.A. Humanisierter tau-antikörper
DK2885010T3 (da) 2012-08-16 2020-02-03 Ipierian Inc Fremgangsmåder til behandling med tauopati
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
ES2495266B8 (es) 2013-02-13 2015-11-12 Consejo Superior De Investigaciones Científicas (Csic) Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer
MX375354B (es) 2013-03-13 2025-03-06 Prothena Biosciences Ltd Anticuerpos que se unen a tau y usos de los mismos.
BR112015023262B8 (pt) 2013-03-15 2024-02-06 Ac Immune Sa Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
KR20140128229A (ko) * 2013-04-26 2014-11-05 한국과학기술연구원 체내 단백질 응집체의 용해를 이용한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 혈액진단키트
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
KR101890978B1 (ko) 2014-06-17 2018-08-24 서울대학교산학협력단 알츠하이머 질환 모델용 형질전환 돼지 및 이의 용도
HRP20210680T1 (hr) 2014-07-10 2021-06-11 Bioarctic Ab POBOLJŠANA PROTUTIJELA KOJA VEŽU Aβ PROTOFIBRIL
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
EA201892412A1 (ru) * 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
CA3022673A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
EP3658172A4 (de) 2017-07-25 2021-05-05 TrueBinding, Inc. Behandlung von krebs durch blockierung der interaktion von tim-3 und seinem liganden
EA202091012A1 (ru) 2017-10-25 2020-08-27 Янссен Фармасьютикалз, Инк. Композиции фосфорилированных тау-пептидов и их применения
JP2022517898A (ja) 2018-11-14 2022-03-11 キナプス 予測モデルを決定するための方法、ｍｋマーカのｋアプレットの進展を予測するための方法および関連デバイス
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
CN113710269A (zh) 2019-02-08 2021-11-26 Ac免疫有限公司 磷酸化Tau肽疫苗的安全施用方法
CN119371527A (zh) 2019-03-03 2025-01-28 普罗塞纳生物科学有限公司 识别tau的抗体
MA55902A (fr) 2019-04-24 2022-03-16 Ac Immune Sa Administration hétérologue de vaccins tau
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271140A (en) 1978-01-23 1981-06-02 Baxter Travenol Laboratories, Inc. Method and composition for double receptor, specific binding assays
US4474892A (en) 1983-02-16 1984-10-02 Board Of Trustees Of The Leland Stanford Junior University Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
JPS6267297A (ja) 1985-09-18 1987-03-26 Hitachi Ltd ポンプの軸受潤滑装置
EP0274826B1 (de) 1986-11-17 1998-08-12 Scios Inc. Rekombiniertes Alzheimer Amyloid-Protein
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5220013A (en) * 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
US5547841A (en) * 1987-10-08 1996-08-20 The Mclean Hospital Corporation In vitro method for screening for drugs that inhibit production or degradation of human A4-amyloid
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
AU5525090A (en) 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
WO1990012871A1 (en) 1989-04-14 1990-11-01 Research Foundation For Mental Hygiene, Inc. Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
US5234814A (en) * 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
AU7121191A (en) 1990-02-26 1991-10-10 Albert Einstein College Of Medicine Of Yeshiva University Diagnostic assay for alzheimer's disease
US5213962A (en) * 1990-04-24 1993-05-25 The Regents Of The University Of California Purification, detection and methods of use of protease Nexin-2
WO1991019810A1 (en) * 1990-06-15 1991-12-26 California Biotechnology Inc. Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
JPH04252955A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd 蛋白質の測定方法、試薬及びキット
JPH04252956A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパク質の測定方法、試薬及びキット
JPH04252954A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパクの測定方法、試薬及びキット
JPH07506720A (ja) 1992-01-07 1995-07-27 アテナ　ニューロサイエンシーズ，　インコーポレイテッド アルツハイマー病のトランスジェニック動物モデル
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
EP1298436B1 (de) 1992-10-26 2010-07-14 Elan Pharmaceuticals, Inc. Verfahren zur Identifizierung von Hemmstoffverbindungen der Freisetzung von Beta-Amyloidpeptid (BAP)
EP0683234B2 (de) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US20030086938A1 (en) 2000-02-21 2003-05-08 Jensen Martin Roland Novel methods for down-regulation of amyloid
WO2003051374A2 (en) * 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
JP4252955B2 (ja) 2002-07-01 2009-04-08 ソニー エリクソン モバイル コミュニケーションズ， エービー 電子通信装置に対してテキストを入力する方法
WO2004039738A1 (ja) 2002-10-29 2004-05-13 Hoya Corporation 化学強化用ガラス、情報記録媒体用基板、情報記録媒体及び情報記録媒体の製造方法
JP4252954B2 (ja) 2004-12-02 2009-04-08 インターナショナル・ビジネス・マシーンズ・コーポレーション 情報処理装置、情報処理装置のパワーマネージメント方法、およびそのためのプログラム

Also Published As

Publication number Publication date
US20040265920A1 (en) 2004-12-30
EP1491889A3 (de) 2005-04-06
CA2205359A1 (en) 1996-05-23
JP2004077499A (ja) 2004-03-11
US20040253643A1 (en) 2004-12-16
US7427392B1 (en) 2008-09-23
WO1996015452A1 (en) 1996-05-23
ES2230551T3 (es) 2005-05-01
PT792458E (pt) 2005-02-28
EP1491889A2 (de) 2004-12-29
US20050069968A1 (en) 2005-03-31
US7700309B2 (en) 2010-04-20
DE69533623T2 (de) 2006-03-02
AU705907B2 (en) 1999-06-03
JP3634375B2 (ja) 2005-03-30
AU4154496A (en) 1996-06-06
JPH10509797A (ja) 1998-09-22
EP0792458A4 (de) 1999-04-07
CA2205359C (en) 2006-07-04
EP0792458A1 (de) 1997-09-03
DK0792458T3 (da) 2005-01-31
EP0792458B1 (de) 2004-10-06
US7811769B2 (en) 2010-10-12
DE69533623D1 (de) 2004-11-11

Similar Documents

Publication Publication Date Title
DE69533623D1 (de) Verfahren zur unterstützung der diagnose der alzheimerschen krankheit durch messung der amyloid-beta-peptide(x groesser als oder gleich 41) und tau
SE9401351D0 (sv) A method for diagnosis
DE69707266D1 (de) Verfahren zum überwachen der gesundheit eines patienten durch messen und vorhersage des glucosespiegels einer blutprobe des patienten
DE10345171A1 (de) Überwachungssystem für Patienten
ATE160875T1 (de) Verfahren zum nachweis und/oder zur bestimmung und/oder zur isolierung von apoptotischen zellen in oder aus einer probe
ATE23067T1 (de) Verfahren und vorrichtung zur selbstueberpruefung von mikrorechnergesteuerten schaltgeraeten, insbesondere in kraftfahrzeugen.
Boston Initial in vitro evaluation of DIAGNOdent for detecting secondary carious lesions associated with resin composite restorations.
EP1226783A3 (de) Verfahren und medizinisches System zur Überwachung eines an Epilepsie leidenden Patienten
DE69221666D1 (de) Verfahren zur Diagnose von Nierenkrankheiten durch Nachweisung von Albuminfragmenten
DE69121990D1 (de) Verfahren zur immunologischen Bestimmung des carboxyterminalen Peptids von Typ-I-Prokollagen
Price et al. Allergy to rabbits: II. Identification and characterization of a major rabbit allergen
DE69304083D1 (de) Drucksignal-Verarbeitungsgerät und Verfahren für ein automatisches Blutdruckmessinstrument
JPH02243951A (ja) 鉄筋コンクリート内部の鋼材の腐食を診断するための方法
Hinrichs et al. A comparison of 3 systems for quantifying gingival crevicular fluid with respect to linearity and the effects of qualitative differences in fluids
NL1024844C2 (nl) Werkwijze en inrichting voor snelle verwerking van meetdata met een veelheid onafhankelijke steekproeven.
ATE445840T1 (de) Immuntest für humanes medullasin und verfahren zur diagnose von multipler sklerose
Mutti et al. Reference values for early markers of renal damage
JP4735503B2 (ja) 腹膜機能マーカー、その分析方法およびその用途
EP0621480A3 (de) Diagnose und Überwachung von Patienten mit Lungenkrebs durch Messung von NCA 50/90 im Blut.
EP0628820A3 (de) Diagnose und Überwachung von Patienten mit Dickdarmkrebs durch Messung von NCA 50/90 im Blut.
Meier-Ruge Morphometric methods and their potential value for gerontological brain research
RU1796143C (ru) Устройство дл определени времени восстановлени парциального давлени кислорода в ткани в постишимическом периоде
JPS62103591A (ja) 体表面モニタ
Hassan et al. Diagnosis of dental erosion using intraoral scanner in comparison to 3D confocal laser microscope
Anyaiwe Pathology and Neuroimaging for Alzheimer’s Disease

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0792458

Country of ref document: EP